NEOG Q3 Deep Dive: Commercial Execution, Innovation, and Operational Progress Shape Outlook

Life sciences company Neogen (NASDAQ:NEOG) reported calendar Q3 2026 (fiscal Q1 2027) results beating Wall Street’s revenue expectations, with sales up 6.5% year on year to $222.8 million. The company expects the full year’s revenue to be around $887.5 million, close to analysts’ estimates. Its non-GAAP profit of $0.08 per share was 50% above analysts’ consensus estimates.